{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:47:15Z","timestamp":1792608435656,"version":"4.5.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2017,12,1]]},"DOI":"10.1001\/jamainternmed.2017.3941","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T19:35:05Z","timestamp":1508441705000},"page":"1755","source":"Crossref","is-referenced-by-count":75,"title":["Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model"],"prefix":"10.1001","volume":"177","author":[{"given":"Abriana","family":"Tasillo","sequence":"first","affiliation":[{"name":"HIV Epidemiology & Outcomes Unit, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Salomon","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Trikalinos","sequence":"additional","affiliation":[{"name":"Center for Evidence-Based Medicine, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"C. Robert","family":"Horsburgh","sequence":"additional","affiliation":[{"name":"Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Marks","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[{"name":"HIV Epidemiology & Outcomes Unit, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"},{"name":"Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"ioi170071r2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1164\/rccm.201101-0181OC","article-title":"Priorities for screening and treatment of latent tuberculosis infection in the United States.","volume":"184","author":"Linas","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"ioi170071r3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2105\/AJPH.2008.149492","article-title":"Overweight and diabetes prevalence among US immigrants.","volume":"100","author":"Oza-Frank","year":"2010","journal-title":"Am J Public Health"},{"issue":"23","key":"ioi170071r4","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection.","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"ioi170071r5","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.","volume":"19","author":"Bliven-Sizemore","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"ioi170071r6","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.5588\/ijtld.13.0423","article-title":"Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.","volume":"17","author":"Shepardson","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"ioi170071r8","first-page":"99","article-title":"Diabetes\u2014United States, 2006 and 2010.","volume":"62","author":"Beckles","year":"2013","journal-title":"MMWR Suppl"},{"issue":"1","key":"ioi170071r9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of Mycobacterium tuberculosis infection.","volume":"27","author":"Pai","year":"2014","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"ioi170071r10","first-page":"471","article-title":"Cost-effectiveness of QuantiFERON-TB test vs tuberculin skin test in the diagnosis of latent tuberculosis infection.","volume":"14","author":"Deuffic-Burban","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"issue":"14","key":"ioi170071r11","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1001\/jama.286.14.1740","article-title":"Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection.","volume":"286","author":"Mazurek","year":"2001","journal-title":"JAMA"},{"issue":"7","key":"ioi170071r12","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1086\/521106","article-title":"Detection of Mycobacterium tuberculosis infection in United States Navy recruits using the tuberculin skin test or whole-blood interferon-gamma release assays.","volume":"45","author":"Mazurek","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"2","key":"ioi170071r13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw694","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children.","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"8","key":"ioi170071r14","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention.","volume":"61","author":"Podany","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"10","key":"ioi170071r15","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"issue":"11","key":"ioi170071r17","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/archinte.167.11.1145","article-title":"Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease.","volume":"167","author":"Franco","year":"2007","journal-title":"Arch Intern Med"},{"issue":"4","key":"ioi170071r18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/MLR.0000000000000308","article-title":"The lifetime medical cost savings from preventing HIV in the United States.","volume":"53","author":"Schackman","year":"2015","journal-title":"Med Care"},{"issue":"2","key":"ioi170071r22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/aje\/kwt246","article-title":"Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup.","volume":"79","author":"Shea","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"11","key":"ioi170071r24","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/01.mlr.0000228021.89490.2a","article-title":"The lifetime cost of current human immunodeficiency virus care in the United States.","volume":"44","author":"Schackman","year":"2006","journal-title":"Med Care"},{"issue":"4","key":"ioi170071r25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s10903-012-9692-5","article-title":"Intensified case-finding for latent tuberculosis infection among the Baltimore City Hispanic population.","volume":"15","author":"Desale","year":"2013","journal-title":"J Immigr Minor Health"},{"issue":"4","key":"ioi170071r26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.5588\/ijtld.12.0697","article-title":"Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada.","volume":"17","author":"Colson","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"ioi170071r27","first-page":"991","article-title":"Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study.","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"ioi170071r28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.tube.2015.04.003","article-title":"Latent tuberculosis infection\u2014revisiting and revising concepts.","volume":"95","author":"Salgame","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"issue":"4","key":"ioi170071r29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.4269\/ajtmh.2006.74.604","article-title":"Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas.","volume":"74","author":"P\u00e9rez","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"ioi170071r30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/acer.2007.31.issue-1","article-title":"Is alcohol use associated with cavitary disease in tuberculosis?","volume":"31","author":"Moran","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"ioi170071r31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3201\/eid1803.111107","article-title":"Using genotyping and geospatial scanning to estimate recent Mycobacterium tuberculosis transmission, United States.","volume":"18","author":"Moonan","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"ioi170071r36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2337\/dc12-2625","article-title":"Economic costs of diabetes in the US in 2012.","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"issue":"12","key":"ioi170071r37","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.2337\/diacare.27.12.2829","article-title":"End-stage renal disease\u2013associated managed care costs among patients with and without diabetes.","volume":"27","author":"Joyce","year":"2004","journal-title":"Diabetes Care"},{"issue":"4","key":"ioi170071r38","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1177\/0272989X08315240","article-title":"Health-state utilities in liver disease: a systematic review.","volume":"28","author":"McLernon","year":"2008","journal-title":"Med Decis Making"},{"issue":"7","key":"ioi170071r39","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/j.1524-4733.2008.00355.x","article-title":"Health state utilities in latent and active tuberculosis.","volume":"11","author":"Guo","year":"2008","journal-title":"Value Health"},{"issue":"11","key":"ioi170071r40","doi-asserted-by":"publisher","first-page":"e0140881","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011-2012.","volume":"10","author":"Miramontes","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"ioi170071r41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/oxfordjournals.aje.a112510","article-title":"Estimating prevalence from the results of a screening test.","volume":"107","author":"Rogan","year":"1978","journal-title":"Am J Epidemiol"},{"key":"ioi170071r42","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis: a general review.","volume":"26","author":"Ferebee","year":"1970","journal-title":"Bibl Tuberc"},{"issue":"9","key":"ioi170071r46","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"ioi170071r47","first-page":"1","volume":"4","author":"Miller","year":"2009","journal-title":""},{"key":"ioi170071r19","volume-title":"2015 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States","author":"United States Renal Data System","year":"2015"},{"key":"ioi170071r20","author":"Forbes","year":"2016"},{"key":"ioi170071r44","volume-title":"Healthcare Cost and Utilization Project National Inpatient Sample","author":"Agency for Healthcare Research and Quality","year":"2015"},{"key":"ioi170071r45","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-Effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"ioi170071r1","unstructured":"Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2014. https:\/\/www.cdc.gov\/tb\/statistics\/reports\/2014\/pdfs\/tb-surveillance-2014-report_updated.pdf. Published October 2015. Accessed January 15, 2017."},{"key":"ioi170071r7","unstructured":"BelknapR, BorisovAS, HollandDP, . Adherence to once-weekly self-administered isoniazid and rifapentine for latent tb infection: iAdhere [abstract 827LB]. Conference on Retroviruses and Opportunistic Infections. http:\/\/www.croiconference.org\/sessions\/adherence-once-weekly-self-administered-inh-and-rifapentine-latent-tb-iadhere. Accessed August 28, 2017."},{"key":"ioi170071r16","unstructured":"Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2014. https:\/\/www.cdc.gov\/tb\/publications\/guidelines\/tb_hiv_drugs\/recommendations04.htm. Updated September 22, 2014. Accessed January 15, 2017."},{"key":"ioi170071r21","unstructured":"United States Census Bureau. Table DP05 - ACS Demographic and Housing Estimates. https:\/\/factfinder.census.gov\/faces\/nav\/jsf\/pages\/index.xhtml. Accessed May 26, 2016."},{"key":"ioi170071r23","unstructured":"National Vital Statistics System. 2013 Mortality Tables. Vol. 6, No. 3. https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr66\/nvsr66_03.pdf. Updated April 11, 2017. Accessed December 14, 2016."},{"key":"ioi170071r32","unstructured":"United States Department of Health and Human Services Center for Medicare Services. Physician fee schedule. http:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched\/index.html?redirect=\/PhysicianFeeSched. Accessed December 22, 2015."},{"key":"ioi170071r33","unstructured":"United States Department of Health and Human Services Center for Medicare Services. Clinical laboratory fee schedule. http:\/\/www.cms.gov\/ClinicalLabFeesched\/. Accessed December 22, 2015."},{"key":"ioi170071r34","unstructured":"Truven Health Analytics. Micromedex 2.0. Drug Topics Red Book Online. http:\/\/www.micromedexsolutions.com. Accessed January 13, 2017."},{"key":"ioi170071r35","unstructured":"Agency for Healthcare Research and Quality. Medical expenditure panel survey. http:\/\/meps.ahrq.gov\/mepsweb\/. Accessed July 15, 2013."},{"key":"ioi170071r43","unstructured":"Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule: details for title: 16CLAB. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched\/Clinical-Laboratory-Fee-Schedule-Files-Items\/16CLAB.html?DLPage=1&DLEntries=10&DLSort=2&DLSortDir=descending. Published December 2015. Accessed May 2016."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/edhub.ama-assn.org\/journals\/jamainternalmedicine\/fullarticle\/2657591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T22:02:50Z","timestamp":1719525770000},"score":1,"resource":{"primary":{"URL":"http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/jamainternmed.2017.3941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2017.3941","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}